MRK - Merck & Co., Inc.
| Previous close | 82.69 |
| Open | 82.70 |
| Bid | 81.38 x 3200 |
| Ask | 81.57 x 800 |
| Day's range | 81.15 - 82.82 |
| 52-week range | 62.38 - 87.07 |
| Volume | 9,618,716 |
| Avg. volume | 10,513,047 |
| Market cap | 209.55B |
| Beta (3Y monthly) | 0.33 |
| PE ratio (TTM) | 25.70 |
| EPS (TTM) | 3.17 |
| Earnings date | 30 Jul 2019 |
| Forward dividend & yield | 2.20 (2.66%) |
| Ex-dividend date | 2019-06-14 |
| 1y target est | 92.14 |
- Zacks•2 days ago
Caterpillar (CAT) Set to Report Q2 Earnings: What to Expect
Caterpillar (CAT) is a company that has had somewhat of a quiet year, with shares up 7.7% year-to-date.
- Zacks•2 days ago
Is a Beat in the Cards for Bristol-Myers (BMY) Q2 Earnings?
Investors will focus on regular top- and bottom-line numbers along with updates on the Celgene merger, when Bristol-Myers (BMY) reports second-quarter results.
- Zacks•2 days ago
Bristol-Myers, Ono, Bayer Team Up for Colorectal Cancer Study
Bristol-Myers (BMY), Ono Pharmaceutical and Bayer ink a collaboration deal to evaluate the combination of Opdivo plus Stivarga for treating micro-satellite stable metastatic colorectal cancer.
- Zacks•2 days ago
Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, Pipeline/Regulatory Updates in Focus
J&J (JNJ) and Novartis (NVS) set the earnings season in motion for the pharma space. FDA approves Merck's (MRK) new combination antibacterial injection, Recarbrio.
- Zacks•2 days ago
Dow 30 Stock Roundup: MSFT, JPM, IBM, JNJ, GS Earnings Impress
The Dow endured a volatile week, primarily due to renewed trade tensions, after gaining strongly earlier this month
- Zacks•3 days ago
3 Key Takeaways From J&J's (JNJ) Q2 Earnings Announcement
Here are some of the highlights of J&J's (JNJ) second-quarter earnings call.
- Zacks•3 days ago
Is a Beat in Store for Glaxo (GSK) This Earnings Season?
Glaxo's (GSK) Vaccines segment is likely to witness sales growth in the second quarter.
- Zacks•3 days ago
Novartis (NVS) Beats on Q2 Earnings & Sales, Raises Guidance
Novartis (NVS) beats sales estimates in the second quarter, driven by robust performance of key drugs and biosimilars.
- Zacks•4 days ago
Seattle Genetics (SGEN) Q2 Loss Narrows, Sales Top Estimates
Seattle Genetics (SGEN) betters loss estimates and rides high on revenue beat in Q2.
- Zacks•4 days ago
Merck's Antibiotic Recarbrio Gets FDA Nod for Infections
The FDA approves Merck's (MRK) anti-bacterial injection, MK-7655A, to be marketed as Recarbrio.
- Zacks•4 days ago
Mallinckrodt (MNK) Discontinues Sclerosis Study on Acthar Gel
Mallinckrodt (MNK) halts its phase IIB study, assessing the efficacy and safety of Acthar Gel as an investigational treatment for amyotrophic lateral sclerosis.
- Business Wire•4 days ago
FDA Approves Merck’s RECARBRIO™ (imipenem, cilastatin, and relebactam) For the Treatment of Adults with Complicated Urinary Tract and Complicated Intra-Abdominal Bacterial Infections Where Limited or No Alternative Treatment Options Are Available
Merck (MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved RECARBRIO™ (imipenem, cilastatin, and relebactam) for injection, 1.25 grams, a new combination antibacterial. RECARBRIO is indicated in patients 18 years of age and older who have limited or no alternative treatment options, for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by the following susceptible Gram-negative microorganisms: Enterobacter cloacae, Escherichia coli, Klebsiella aerogenes, Klebsiella pneumoniae, and Pseudomonas aeruginosa. RECARBRIO is also indicated in patients 18 years of age or older who have limited or no alternative treatment options, for the treatment of complicated intra-abdominal infections (cIAI) caused by the following susceptible Gram-negative microorganisms: Bacteroides caccae, Bacteroides fragilis, Bacteroides ovatus, Bacteroides stercoris, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Fusobacterium nucleatum, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Parabacteroides distasonis and Pseudomonas aeruginosa.
- Zacks•5 days ago
Merck (MRK) Gains As Market Dips: What You Should Know
Merck (MRK) closed the most recent trading day at $81.59, moving +0.78% from the previous trading session.
- Zacks•5 days ago
Is a Beat in the Cards for Novartis' (NVS) Q2 Earnings?
Investors will focus on regular top- and bottom-line numbers along with pipeline updates when Novartis (NVS) reports second-quarter results.
- Zacks•5 days ago
Glaxo's Zejula Meets Goal in First-Line Ovarian Cancer Study
Glaxo's (GSK) phase III study evaluating Zejula as a first-line maintenance therapy in patients with ovarian cancer meets the primary endpoint.
- Zacks•5 days ago
The Zacks Analyst Blog Highlights: Cisco, Home Depot, Merck, Humana and Public Service Enterprise
The Zacks Analyst Blog Highlights: Cisco, Home Depot, Merck, Humana and Public Service Enterprise
- Zacks•5 days ago
J&J (JNJ) Beats on Q2 Earnings, Ups 2019 Sales Growth View
J&J (JNJ) beats estimates for both earnings and sales in the second quarter of 2019 and raises 2019 guidance for operational sales growth for the second time this year.
- Zacks•6 days ago
Top Stock Reports for Cisco, Home Depot & Merck
Top Stock Reports for Cisco, Home Depot & Merck
- Zacks•6 days ago
J&J Falls Amid Reports of Criminal Probe Into Talcum Powder
The U.S. Justice Department is reportedly pursuing a criminal investigation as to whether J&J (JNJ) lied about the possible cancer risk associated with its talcum powder.
- Reuters - UK Focus•6 days ago
UPDATE 2-GSK drug helps ovarian cancer patients live longer in late-stage study
GlaxoSmithKline Plc's cancer treatment Zejula met the main goal of helping patients with ovarian cancer live longer without their disease worsening in a late-stage study, the company said on Monday. The company bought the drug when it acquired U.S. cancer specialist Tesaro for $5.1 billion in December and Zejula is already approved for certain ovarian cancer patients. For GSK, the success of Zejula would help it access a wider population group and give it an edge over rival PARP inhibitors such as AstraZeneca and Merck & Co's Lynparza and Clovis Oncology's Rubraca.
- Motley Fool•8 days ago
Better Buy: AbbVie vs. Merck
Which stock wins in a head-to-head matchup between these two big drugmakers?
- CNBC•9 days ago
Stocks making the biggest moves midday: Johnson & Johnson, Stitch Fix, Illumina, Merck & more
These are the stocks posting the largest moves in midday trading.
- Zacks•9 days ago
Drug Pricing Woes Linger on Repealing Drug Rebate Proposal
Investors' skepticism runs rife as Trump drops the drug rebate proposal, pushing drugmakers to take center stage with regard to the controversial drug pricing issue.
- Zacks•9 days ago
AstraZeneca's Imfinzi Gains Orphan Drug Status for SCLC
The FDA assigns an orphan drug designation to AstraZeneca's (AZN) Imfinzi for the treatment of small cell lung cancer, the most aggressive type of the ailment.
- Zacks•9 days ago
Dow Breezes Past 27,000: 4 Blue-Chip Stocks to Buy
The 30-stock index closes above the 27,000 mark for the first time. It took nearly 372 days for the blue-chip index to cross the 27,000 mark from when it reached the 26,000 mark in January 2018.
